Evidence map›Paper›PMID 26311893›Full record

ArticleJournal of virology2015

Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Rajesh P Ringe, Anila Yasmeen, Gabriel Ozorowski, Eden P Go, Laura K Pritchard, Miklos Guttman, Thomas A Ketas, Christopher A Cottrell, Ian A Wilson, Rogier W Sanders and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. The Versatile Manipulations of Self-Assembled Proteins in Vaccine Design.International journal of molecular sciences · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Rajesh P RingeDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Anila YasmeenDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Gabriel OzorowskiDepartment of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA.
Eden P GoDepartment of Chemistry, University of Kansas, Lawrence, Kansas, USA.
Laura K PritchardOxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
Miklos GuttmanDepartment of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.
Thomas A KetasDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Christopher A CottrellDepartment of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
Rogier W SandersDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Albert CupoDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Max CrispinOxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
Kelly K LeeDepartment of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.
Heather DesaireDepartment of Chemistry, University of Kansas, Lawrence, Kansas, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA.
P J KlasseDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
John P MooreDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA jpm2003@med.cornell.edu.
Cornell University · USScripps Research Institute · USUniversity of Kansas · USUniversity of Oxford · GBUniversity of Washington · USAcademic Medical Center · NL

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CRISPIN, MAX · 2012 to 2018
$131.5M
Structural studies of native-like SOSIP trimersP01AI110657 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2015 to 2024
$35.4M
Trimer Production and Immunogenicity TestingP01AI082362 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2009 to 2014
$16.0M
NEUTRALIZATION OF PRIMARY HIV1 VIRUSESR37AI036082 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 1998 to 2017
$7.0M
Characterization of PTMs on Env to support HIV vaccine developmentR01AI094797 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DESAIRE, HEATHER R · 2012 to 2015
$1.4M
Biophysical Signatures in HIV-1 Env Correlating with Mother-to-Child TransmissionR21AI112389 · NIAID · UNIVERSITY OF WASHINGTON · PI LEE, KELLY KEISEN · 2014 to 2015
$471k
NIAID NIH HHS 1UM1 AI100663NIAID NIH HHS P01 AI082362NIAID NIH HHS P01 AI110657NIAID NIH HHS R01 AI094797NIAID NIH HHS R21 AI112389NIAID NIH HHS R37 AI036082NIAID NIH HHS R37 AI36082NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

unlabelledWe have investigated factors that influence the production of native-like soluble, recombinant trimers based on the env genes of two isolates of human immunodeficiency virus type 1 (HIV-1), specifically 92UG037.8 (clade A) and CZA97.012 (clade C). When the recombinant trimers based on the env genes of isolates 92UG037.8 and CZA97.012 were made according to the SOSIP.664 design and purified by affinity chromatography using broadly neutralizing antibodies (bNAbs) against quaternary epitopes (PGT145 and PGT151, respectively), the resulting trimers are highly stable and they are fully native-like when visualized by negative-stain electron microscopy. They also have a native-like (i.e., abundant) oligomannose glycan composition and display multiple bNAb epitopes while occluding those for nonneutralizing antibodies. In contrast, uncleaved, histidine-tagged Foldon (Fd) domain-containing gp140 proteins (gp140UNC-Fd-His), based on the same env genes, very rarely form native-like trimers, a finding that is consistent with their antigenic and biophysical properties and glycan composition. The addition of a 20-residue flexible linker (FL20) between the gp120 and gp41 ectodomain (gp41ECTO) subunits to make the uncleaved 92UG037.8 gp140-FL20 construct is not sufficient to create a native-like trimer, but a small percentage of native-like trimers were produced when an I559P substitution in gp41ECTO was also present. The further addition of a disulfide bond (SOS) to link the gp120 and gp41 subunits in the uncleaved gp140-FL20-SOSIP protein increases native-like trimer formation to ∼20 to 30%. Analysis of the disulfide bond content shows that misfolded gp120 subunits are abundant in uncleaved CZA97.012 gp140UNC-Fd-His proteins but very rare in native-like trimer populations. The design and stabilization method and the purification strategy are, therefore, all important influences on the quality of trimeric Env proteins and hence their suitability as vaccine components. IMPORTANCE: Soluble, recombinant multimeric proteins based on the HIV-1 env gene are current candidate immunogens for vaccine trials in humans. These proteins are generally designed to mimic the native trimeric envelope glycoprotein (Env) that is the target of virus-neutralizing antibodies on the surfaces of virions. The underlying hypothesis is that an Env-mimetic protein may be able to induce antibodies that can neutralize the virus broadly and potently enough for a vaccine to be protective. Multiple different designs for Env-mimetic trimers have been put forth. Here, we used the CZA97.012 and 92UG037.8 env genes to compare some of these designs and determine which ones best mimic virus-associated Env trimers. We conclude that the most widely used versions of CZA97.012 and 92UG037.8 oligomeric Env proteins do not resemble the trimeric Env glycoprotein on HIV-1 viruses, which has implications for the design and interpretation of ongoing or proposed clinical trials of these proteins.

Indexed as

Antibodies, MonoclonalCalorimetry, Differential ScanningChromatography, AffinityChromatography, LiquidElectrophoresis, Polyacrylamide Gelenv Gene Products, Human Immunodeficiency VirusEnzyme-Linked Immunosorbent AssayHIV-1Mass SpectrometryMicroscopy, ElectronNeutralization TestsProtein EngineeringProtein MultimerizationProtein Structure, TertiaryRecombinant ProteinsSurface Plasmon ResonanceAntibodies, Monoclonalenv Gene Products, Human Immunodeficiency VirusRecombinant Proteins

Identifiers

PMID26311893
PMCPMC4645310
OpenAlexW1943730394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.